Mannitol Biosedra

Mannitol, the active ingredient in Mannitol Biosedra, is an osmotic diuretic presented as a solution for injection for intravenous use. It reduces elevated intracranial pressure, assists in managing cerebral edema, and promotes diuresis in acute renal failure or toxic ingestions.

GNH USA supplies Mannitol Biosedra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory support for cross‑border distribution. Products are shipped with full documentation to meet local health authority requirements.

Mannitol is used in clinical situations that require osmotic reduction of fluid compartments, particularly in the central nervous system and renal contexts.

Elevated intracranial pressure: lowers pressure and helps resolve cerebral edema. Acute renal failure: enhances urine output to assist fluid balance. Toxic ingestions (e.g., certain drug overdoses): increases renal clearance of harmful substances.

Mannitol may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Headache: mild to moderate pain often related to rapid osmotic shifts. - Nausea or vomiting: gastrointestinal discomfort after infusion. - Transient hypotension: temporary drop in blood pressure during or shortly after administration.

Serious or Rare Side Effects: - Acute renal failure: worsening kidney function in susceptible patients. - Pulmonary edema: fluid accumulation in lungs due to rapid volume shifts. - Severe electrolyte disturbances: hypernatremia or severe hypokalemia requiring medical intervention.

When using Mannitol Biosedra, clinicians should observe several safety measures. - Assess renal function: evaluate creatinine clearance before initiating therapy. - Monitor fluid balance: track input, output, and weight to avoid overload. - Check electrolytes: regularly measure serum sodium, potassium, and osmolality. - Use caution in patients with heart failure: risk of volume overload. - Avoid rapid infusion rates: administer over recommended time to reduce neurologic symptoms. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Mannitol can interact with other medicines, requiring attention to potential additive effects.

Major Interactions (Avoid): - Loop diuretics (e.g., furosemide): additive diuretic effect may cause severe dehydration and electrolyte loss. - Nephrotoxic agents (e.g., aminoglycosides, amphotericin B): increased risk of renal impairment when combined with Mannitol.

Moderate Interactions (Monitor Closely): - Antihypertensives (e.g., ACE inhibitors, ARBs): may potentiate hypotensive response. - Insulin or oral hypoglycemics: osmotic shifts can affect glucose control, requiring monitoring. - Lithium: altered renal clearance may increase lithium levels.